TargetRNA · Targeting RNA with small molecules
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2024-09-01 → 2028-08-31
- Финансиране от ЕС
- 4 281 898 €
- Участници
- 17
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите.
Накратко на български
Молекули с малък размер се разработват, за да се свързват с РНК и да действат като антимикробни средства. Това помага за избирателна промяна на бактериите в човешкия червен腸ник, което има значение за медицината.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
RNA molecules play key roles in biological processes and diseases. An emerging avenue to develop innovative medicines is therefore to design small molecule drugs that bind to RNA and affect downstream biological functions. However, to advance this field of research, a new generation of scientists is needed that can further develop and ultimately master the challenging process of drug design applied to RNA. Therefore, the TargetRNA network aims to educate and nurture the next generation of scientists with cutting-edge interdisciplinary skills in the discovery and biological characterization of RNA modulators and thus generate fundamental knowledge on what drives affinity and specificity of small molecules binding to RNA. The objective of TargetRNA is to develop compounds with antimicrobial activity through their interaction with RNA targets, and to use these to selectively reshape the human gut microbiome, an area with vast implications for medicine. Training through research activities, spanning from computational and medicinal chemistry over structural and molecular biology to microbiology and in vivo models, will be supplemented by an innovative training programme in specific and transferable skills for interdisciplinary drug discovery strategies to target RNA, including FAIR data principles, open science practices as well as responsible development and sustainable implementation of new innovations. To achieve the ambitious research and training goals, the TargetRNA network unites leading scientists from 13 academic partners (8 beneficiaries, 5 associated) and 4 industry partners (1 beneficiary, 3 associated) based in 9 countries.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITETET I BERGEN · BergenКоординаторНорвегия
- ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA · BolognaИталия
- ASTRAZENECA AB · SodertaeljeШвеция
- CrystalsFirst GmbH · MarburgГермания
- DANMARKS TEKNISKE UNIVERSITET · Kongens LyngbyДания
- EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) · BerlinГермания
- FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA · GenovaИталия
- JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN · Frankfurt Am MainГермания
- LINKOPINGS UNIVERSITET · LinkopingШвеция
- MALVERN PANALYTICAL LIMITED · MALVERNОбединеното кралство
- STICHTING RADBOUD UNIVERSITEIT · NijmegenНидерландия
- SWANSEA UNIVERSITY · SwanseaОбединеното кралство
- Saverna Therapeutics AG · Biel-BenkenШвейцария
- TECHNISCHE HOCHSCHULE MANNHEIM · MannheimГермания
- UNIVERSITAT BASEL · BaselШвейцария
- UNIVERSITE COTE D'AZUR · NiceФранция
- UPPSALA UNIVERSITET · UppsalaШвеция
Връзки
Данни: CORDIS, © Европейски съюз
